[go: up one dir, main page]

AR131380A1 - Purinas 2,6,9-trisustituidas - Google Patents

Purinas 2,6,9-trisustituidas

Info

Publication number
AR131380A1
AR131380A1 ARP230103410A ARP230103410A AR131380A1 AR 131380 A1 AR131380 A1 AR 131380A1 AR P230103410 A ARP230103410 A AR P230103410A AR P230103410 A ARP230103410 A AR P230103410A AR 131380 A1 AR131380 A1 AR 131380A1
Authority
AR
Argentina
Prior art keywords
compounds
salts
trisubstituted purines
trisubstituted
purines
Prior art date
Application number
ARP230103410A
Other languages
English (en)
Inventor
Bernard Barlaam
Michael Bodnarchuk
Frederick Goldberg
Avipsa Ghosh
Sudhir Hande
Phillip Lichtor
Kun Song
Qibin Su
Reem Telmesani
James Sheppeck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR131380A1 publication Critical patent/AR131380A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos que tienen la estructura de fórmula (1) y sales farmacéuticamente aceptables de la misma, en donde R¹, R², R³, R⁴, y R⁵ son como se define en la especificación; composiciones farmacéuticas que comprenden estos compuestos y sales; uso de estos compuestos y sales para tratar o prevenir condiciones mediadas por cinasa 2 dependiente de ciclina (CDK2); kits que comprenden estos compuestos y sales; y métodos para fabricar estos compuestos y sales.
ARP230103410A 2022-12-16 2023-12-15 Purinas 2,6,9-trisustituidas AR131380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263387734P 2022-12-16 2022-12-16

Publications (1)

Publication Number Publication Date
AR131380A1 true AR131380A1 (es) 2025-03-12

Family

ID=89473830

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103410A AR131380A1 (es) 2022-12-16 2023-12-15 Purinas 2,6,9-trisustituidas

Country Status (14)

Country Link
US (2) US20240247001A1 (es)
EP (1) EP4634186A1 (es)
KR (1) KR20250121114A (es)
CN (1) CN120359223A (es)
AR (1) AR131380A1 (es)
AU (1) AU2023393410A1 (es)
CL (1) CL2025001706A1 (es)
CO (1) CO2025009649A2 (es)
CR (1) CR20250283A (es)
DO (1) DOP2025000143A (es)
IL (1) IL321433A (es)
MX (1) MX2025006884A (es)
TW (1) TW202440578A (es)
WO (1) WO2024127350A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025202991A1 (en) * 2024-03-29 2025-10-02 Astrazeneca Ab Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl)amino)-pyrrolidine-1-sulfonamide
CN119462661A (zh) * 2024-09-24 2025-02-18 烟台皓元生物医药科技有限公司 一种azd-8421及其中间体的制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432164A (en) 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
AU2022597A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033590A1 (en) 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ES2246829T3 (es) 1999-02-01 2006-03-01 Cv Therapeutics Inc Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina.
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2793794B1 (fr) 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
BR0014076A (pt) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
DE60138140D1 (de) 2000-10-31 2009-05-07 Aventis Pharma Inc Acyl- und sulfonylderivative 6,9-disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel
CA2463507A1 (en) 2001-10-12 2003-04-17 Sheng Ding Methods for the synthesis of substituted purines
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
ES2283788T3 (es) 2002-06-27 2007-11-01 F. Hoffmann-La Roche Ag Sintesis de derivados de purina.
EP1590359A2 (en) 2003-02-03 2005-11-02 CV Therapeutics Inc. PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
MXPA06001758A (es) 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
JP2006056879A (ja) 2004-07-21 2006-03-02 Kobe Univ インスリン抵抗性の改善剤、及びそのスクリーニング方法
CA2609117A1 (en) 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
BRPI0614502A2 (pt) 2005-07-30 2011-03-29 Astrazeneca Ab Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto
US20100022531A1 (en) 2005-09-01 2010-01-28 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
GB0606283D0 (en) 2006-03-29 2006-05-10 Cyclacel Ltd Process
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
KR20090112732A (ko) 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
CA2721586A1 (en) 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
EP2550260A1 (en) 2010-03-24 2013-01-30 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
PT2592933T (pt) 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
EP2630136A1 (en) 2010-10-21 2013-08-28 Universität des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
EP2696682B1 (en) 2011-04-13 2018-03-21 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
KR102527562B1 (ko) 2011-09-09 2023-05-03 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
ES2795418T3 (es) 2012-02-17 2020-11-23 Res Triangle Inst Derivados de difenil purina restringidos periféricamente
CN104918940B (zh) 2012-11-16 2017-03-08 默沙东公司 人磷脂酰肌醇3‑激酶δ的嘌呤抑制剂
US20140275178A1 (en) 2013-03-13 2014-09-18 Musc Foundation For Research Development Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
WO2014189830A1 (en) 2013-05-20 2014-11-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Calcium channel agonists
US10519160B2 (en) 2014-07-18 2019-12-31 The General Hospital Corporation Imaging agents for neural flux
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US20180000814A1 (en) 2016-06-14 2018-01-04 Joseph Hacia Compositions and methods for the treatment of zellweger spectrum disorder
AU2017315572B2 (en) 2016-08-23 2021-07-15 Beijing Innocare Pharma Tech Co., Ltd. Fused heterocyclic derivative, preparation method therefor and medical use thereof
KR101893879B1 (ko) 2017-03-31 2018-09-03 한국화학연구원 신규한 cdk 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 cdk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2018200527A1 (en) 2017-04-24 2018-11-01 Mercaptor Discoveries, Inc. Use of thiol compounds to treat neurological disease
EP3619211A1 (en) 2017-05-03 2020-03-11 Université Grenoble Alpes Method for synthesizing diversely substituted purines
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
KR20210071976A (ko) 2018-09-04 2021-06-16 마젠타 테라퓨틱스 인코포레이티드 아릴 하이드로카본 수용체 길항제 및 사용 방법
BR112021008742A2 (pt) 2018-11-05 2021-08-10 Avista Pharma Solutions, Inc. compostos químicos
MX2021006731A (es) 2018-12-07 2021-09-23 Univ Maryland Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
CN113330000B (zh) 2019-01-31 2024-12-24 辉瑞公司 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物
US20230063230A1 (en) 2019-02-19 2023-03-02 The Regents Of The University Of California Nurr1 receptor modulators
KR20210135544A (ko) 2019-03-05 2021-11-15 에프-스타 테라퓨틱스 인코포레이티드 질병 치료를 위한 화합물, 조성물, 및 방법
CN111825674A (zh) 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN114025758A (zh) 2019-07-01 2022-02-08 钱立刚 P2x7r拮抗剂
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
CN113024563B (zh) 2019-12-24 2023-01-03 药康众拓(江苏)医药科技有限公司 嘧啶并五元杂环类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
US20230140941A1 (en) 2020-03-13 2023-05-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
WO2021226137A1 (en) 2020-05-04 2021-11-11 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing immune responses to infectious agents
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
TW202212331A (zh) 2020-09-22 2022-04-01 英屬開曼群島商百濟神州有限公司 作為ｅｇｆｒ抑製劑之吲哚啉化合物及衍生物
US20240050428A1 (en) 2020-10-07 2024-02-15 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
EP4284414A4 (en) 2021-01-26 2025-05-14 Sigilon Therapeutics, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES
US20240374507A1 (en) 2021-01-26 2024-11-14 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing antigen-specific immune tolerance
US20250000788A1 (en) 2021-01-26 2025-01-02 Sigilon Therapeutics, Inc. Biocompatible devices for cell-based therapies and related methods
MX2023015245A (es) 2021-06-16 2024-01-19 Blueprint Medicines Corp Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.
CA3223223A1 (en) 2021-06-28 2023-01-05 Blueprint Medicines Corporation Cdk2 inhibitors
CN116813621A (zh) 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Also Published As

Publication number Publication date
US20240247001A1 (en) 2024-07-25
US12441744B2 (en) 2025-10-14
CO2025009649A2 (es) 2025-08-08
CL2025001706A1 (es) 2025-08-18
MX2025006884A (es) 2025-07-01
KR20250121114A (ko) 2025-08-11
TW202440578A (zh) 2024-10-16
IL321433A (en) 2025-08-01
US20250197425A1 (en) 2025-06-19
DOP2025000143A (es) 2025-08-15
EP4634186A1 (en) 2025-10-22
CN120359223A (zh) 2025-07-22
CR20250283A (es) 2025-08-21
AU2023393410A1 (en) 2025-07-31
WO2024127350A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
AR131380A1 (es) Purinas 2,6,9-trisustituidas
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
MX2021014096A (es) Compuestos heterociclicos, metodos de preparacion y usos de estos.
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
PA8680701A1 (es) Derivados de oxindol
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
CO5700751A2 (es) Derivados de 4-(6-cloro-2,3-metilendioxianilino)-7 (alcoxi sustituiidos)-5-tetrahidropiran-4-iloxiquinazolina como inhibidores de la enzima tirosina quinasa no receptora y composiciones que los contienen
CY1116281T1 (el) Ιμιδαζο[4,5-c]κινολινες ως αναστολεις dna-pk
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
UY28516A1 (es) Derivados de quinazolina
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
AR072622A1 (es) Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas
AR059320A1 (es) Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
MX2025001108A (es) Inhibidores de cinasas aminoheteroarílicos.
BR112022026386A2 (pt) Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
CO2024014595A2 (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
BR112022001158A2 (pt) Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidina
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos